Risedronic acid prevents bone loss in postmenopausal women with breast cancer, with or without aromatase inhibitor (AI) therapy,

Author：

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1637, 2008-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 25, Iss. 10, 2009-10 ,pp. : 23-26

Adis International

Access to resources Recommend Favorite

Denosumab HALTs bone loss during AI therapy for breast cancer

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Weekly ibandronic acid prevents postmenopausal bone loss

Inpharma, Vol. 1, Iss. 1406, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Clinical Dosage Determination of a New Aromatase Inhibitor, Anastrozole, in Postmenopausal Japanese Women with Advanced Breast Cancer

By Nomura Y.

Clinical Drug Investigation, Vol. 20, Iss. 5, 2000-11 ,pp. : 357-369

Adis International

Access to resources Recommend Favorite

Risedronic acid abrogates anastrozole-induced bone loss

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite